Alantra advises on the acquisition of Fishawack Health by Bridgepoint
Alantra, the independent global mid-market investment banking, asset management and credit portfolio advisory firm, has advised Bridgepoint on its acquisition of Fishawack Health, the UK-headquartered global healthcare communications agency, from mid-market private equity investor LDC. Simultaneously, Fishawack Health announced the acquisition of Skysis, a specialist strategic and market access consulting company based in the US that is focused on the pharma and biopharmaceutical industry.
Established in 2001, Fishawack Health has become one of the largest independent healthcare communications organisations in the world. It has 14 offices in Europe and the US and a highly skilled workforce of 850 employees. The company’s strategic and scientific focus makes it ideally placed to solve complex brand, portfolio and enterprise level challenges for healthcare and pharmaceutical organisations.
Fishawack Health specialises in three areas – medical communications, commercial and marketing strategy, and commercial execution. Each of these capabilities work independently or combine as one unit, complete with tailored teams which are built bespoke to the client’s individual needs and challenges. The organisation serves more than 100 customers across 300 different drug compounds, including all the top 20 global pharmaceutical companies and a range of innovative biotech and medical device companies.
Anthony Harrington, partner at Alantra who led the deal, commented, “We have known the Fishawack team for some time and we’re delighted they have found a highly supportive partner in Bridgepoint to support the exciting growth plans for the business.”
He added, “Fishawack is an example of a business at the forefront of the healthcare communications and consulting sector. It has demonstrated impressive long-term revenue growth, the ability to acquire other smaller firms and integrate them successfully, and has proved adept at finding and retaining talented employees. It is these characteristics that are attracting rising levels of private equity investment into this market.”
Oct 2020Buy-side advisoryOct 2020SECTOR HealthcareService M&A
Oct 2020InvestmentOct 2020SECTOR HealthcareService Strategic Advisory
Sep 2020Buy-side advisoryValue CHF 435 millionSep 2020SECTOR HealthcareService M&AValue CHF 435 million
Sep 2020Sell-side advisorySep 2020SECTOR HealthcareService M&A